SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet
technology company offering healthcare professionals the online
healthcare information, professional training and educational
services platform and patients the patient management platform,
today announced the launch of its multidisciplinary treatment
("MDT") clinical thinking training platform for hematology
("Hematology MDT Platform"). The Hematology MDT Platform provides
clinicians with a channel to learn multidisciplinary thinking
skills online, in order to improve diagnosis and treatment and
further the efficiency of treatment. MDT is a medical service model
in which multidisciplinary specialists discuss cases of a certain
disease or a systemic disease and then develop an optimal treatment
plan for the patient taking into considerations of opinions from
all disciplines. Experienced physicians are essential and needed to
organize and implement the MDT model as the model requires
standardized multidisciplinary collaboration with high-level
patient participation.
The Hematology MDT Platform is an online learning platform for
front-line physicians, adopting Web real-time communication, or
WebRTC technology where there are MDT theory module, practical
exercise module, expert guidance module, and core issue interactive
discussion module. Physicians can log in to Zhongchao's MDMOOC
platform to submit cases and problems encountered during patient
consultation and treatment and seek solutions from
multidisciplinary experts in real-time. In addition, physicians can
watch MDT training videos to learn the clinical thinking skills
from experts and improve their problem-solving ability during the
disease diagnosis and treatment.
The Hematology MDT Platform has gathered many authoritative
experts in multiple disciplines related to hematology, including
experts and front-line clinicians in hematology, infectious
diseases, microbiology, immunology, blood transplantation from the
Chinese Medical Association, Chinese Medical Doctor Association,
ECCMID, Peking University People's Hospital, The First Affiliate
Hospital of GUANGZHOU Medical
University, 301 Hospital, Fudan University Zhongshan Hospital,
Shanghai Tongji Hospital, Ruijin Hospital, Army Medical University
Affiliated Hospital, Chongqing Medical University No.1 Affiliated
Hospital, Hainan General Hospital, Shenzhen People's Hospital, The
First Affiliated Hospital of College of Medicine Zhejiang
University and The Second Affiliated Hospital of College of
Medicine Zhejiang University. As of August
2021, more than 10,000 physicians have logged into the
Hematology MDT Platform to participate in learning and
discussion.
In the United States, MDT has
been widely used to diagnose of and treat complex diseases such as
cancer, cardiovascular diseases, and neurological diseases, with
more than 90% of large hospitals using the MDT model. According to
the list of the first batch of pilot hospitals for
multidisciplinary diagnosis and treatment for tumor (digestive
system) announced by the National Health Care Commission on
November 30, 2018, there were 231
tertiary class A hospitals implementing MDT in China, accounting for 16% of tertiary class A
hospitals and 9% of tertiary hospitals. As a result, the management
of the Company believes that there is a huge demand for the
application and popularization of MDT model in China. Zhongchao's Hematology MDT platform
provides physicians with a convenient and rapid access to learn and
exchange MDT practices and experiences and will promote the
development of hematology treatment models in China. Looking forward, Zhongchao hopes to
apply its MDT model to other treatment areas, promote the
popularization and development of MDT in China, and improve medical treatment
efficiency and quality.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is
a platform-based internet technology company. It
provides online healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. Through its subsidiaries, the Company
also operates a platform offering patient management services. More
information about the Company can be found at its investor
relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions; the
growth of the professional training and educational services market
in China and the other
international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-launches-hematology-mdt-training-platform-to-improve-diagnosis-and-treatment-301379271.html
SOURCE Zhongchao Inc.